A rational explanation might be that patients of INSS 4S and INRG MS are indeed special subgroups with favorable clinical prognosis, and the MYCN amplification was corroborated as a direct factor initiating high-risk NB and represented a subgroup with poor prognosis. The gene discussed is MYCN; the disease is neuroblastoma.